SRC and head and neck cancer: Most recently, we found that insufficient suppression of the AKT signaling is a major mechanism associated with decrease clinical benefits of Src-targeted treatment in patients with head and neck cancer, and co-inhibition of Src and AKT shows promise for achieving superior anticancer effects in those patients harboring these activations [11].